CD52 and primary cutaneous T-cell non-Hodgkin lymphoma: This effect was consistently observed across two different cell-surface targeted antibodies relevant for CTCL (anti-CD52-mAb and anti-CCR4-mAb), which was validated through two distinct experimental approaches: flow cytometry (Fig. 4d and Fig. 4e) and the lactate dehydrogenase (LDH) release assay (Fig. 4f).